查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087633

結核病檢測市場：2026-2032年全球市場預測（依檢測類型、技術、檢體類型、最終用戶、通路和應用分類）

Tuberculosis Testing Market by Test Type, Technology, Sample Type, End User, Distribution Channel, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，結核病檢測市場將成長至 36.8 億美元，複合年成長率為 6.60%。

主要市場統計數據
基準年 2025 23.5億美元
預計年份：2026年 24.9億美元
預測年份 2032 36.8億美元
複合年成長率 (%) 6.60%

結核病檢測在全球結核病控制中發揮核心作用，因為及時診斷決定著患者能否接受根治性治療、能否評估抗藥性以及能否獲得公共衛生後續訪問。根據世界衛生組織（世衛組織）估計，到2023年，全球將有1,080萬人罹患結核病，125萬人將死於該疾病，凸顯了建立更快速、更便捷的診斷管道的必要性。

結核病檢測領域包括結核菌素皮膚試驗、 干擾素釋放試驗、塗片顯微鏡檢查、培養試驗、核酸增幅檢查、線性探針檢測以及針對高危險群的尿脂阿拉伯甘露聚醣檢測。世界衛生組織建議將快速分子診斷作為有症狀患者的初始檢測方法，同時，對抗藥性結核病的監測需求日益成長，以及在包括愛滋病毒感染者、家庭密切接觸者、移民、囚犯以及糖尿病或免疫抑制患者在內的弱勢群體中擴大篩檢，這些因素共同推動了檢測需求的成長。

結核病檢測方式的革命性變革。

結核病檢測的格局正從以顯微鏡檢查為中心的工作流程轉向快速分子診斷、分散式檢體和綜合抗藥性檢測。雖然培養仍然是全面藥物敏感性檢測的必要手段，但核酸增幅檢查（NAATs）可在數小時內識別結核分枝桿菌及其利福平抗藥性，幫助臨床醫生儘早啟動適當的治療，並支持公共衛生團隊切斷感染鏈。

人工智慧對結核病檢測的累積影響

人工智慧正透過電腦輔助胸部X光相片檢測、自動化檢查室品質檢查、工作流程優先排序和預測性外展等方式，對推廣檢測產生日益顯著的影響。世界衛生組織指出，當與適當的校準和確認性檢測結合使用時，電腦輔助檢測軟體可以取代放射科醫生，用於15歲及​​以上人群的結核病篩檢和分診。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區仍是結核病檢測負擔最重的地區，尤其是在印度、中國、印尼和菲律賓等高發生率國家。優先發展快速分子診斷、加強私部門報告、進行社區篩檢和抗藥性檢測是提高病例發現率和縮短治療時間的關鍵。亞太地區人口眾多，醫療保健服務水準參差不齊，且各國都制定了結核病根除策略，這使得該地區成為結核病分子診斷、數位胸部X光篩檢和加強檢查室網路建設的中心樞紐。

主要集團的發展趨勢：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

無論結核病感染負擔高低，東南亞國協在擴大結核病分子診斷、數位胸部X光篩檢和社區病例發現的範圍，以應對持續感染。海灣合作理事會強調對勞動力篩檢、制定移民健康規程、加強集中式檢查室品管，並在高流動性族群中預防感染。歐盟支持標準化監測、跨境報告、抗生素抗藥性監測以及對高風險族群潛伏性結核感染的管理，其檢測策略以低發病率根除目標和與移民相關的健康優先事項為指導。

主要結核病檢測市場的關鍵國家特定趨勢

儘管美國和加拿大結核病發病率較低，但它們主要依靠檢測、接觸者追蹤以及對高風險族群（包括出生於結核病高負擔國家的人群、愛滋病毒感染者和免疫力缺乏低下者）進行潛伏性結核病篩檢。墨西哥和巴西面臨更嚴峻的公共衛生挑戰，分子診斷技術有助於在都市區、偏遠和醫療服務不足的社區進行早期檢測。英國、德國、法國、義大利和西班牙則著重於移民篩檢、檢查室品管、接觸者追蹤和潛伏性結核病的預防。同時，鑑於俄羅斯抗藥性結核病的嚴重程度，該國仍然是診斷多重抗藥性結核病和利福平抗藥性結核病的重點國家。

為結核病檢測行業的領導者提供的實用建議

產業領導者應產品系列與世界衛生組織建議的診斷演算法保持一致，特別是用於檢測結核病和關鍵抗藥性標記的快速分子檢測。商業策略應優先考慮價格可負擔性、試劑盒供應、儀器運轉率、生物安全性、檢體物流以及適用於中心檢查室、區域醫院、移動篩檢項目和分散式醫療機構的服務模式。

調查方法

本執行摘要基於公共衛生和科學領域權威資料的系統性回顧，包括世界衛生組織指南、國家結核病控制規劃優先事項、美國疾病管制與預防中心和歐洲疾病預防控制中心資訊來源、同行評審的診斷證據、監管趨勢以及公開的衛生政策資訊。研究成果源自於對疾病負擔、檢測流程、採購模式、診斷技術應用、篩檢指南和檢查室實施等因素的多面向橫斷面分析。

結論

結核病檢測正朝著更快、更協調、以患者為中心的診斷模式發展。快速分子檢測、標靶篩檢、抗藥性檢測、人工智慧輔助分診以及數位化醫療協作的結合，對於全球結核病控制計畫和醫療服務提供者至關重要，因為他們致力於控制感染傳播、改善治療效果並應對持續存在的診斷挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 結核病檢測市場：依檢測類型分類

  • 培養試驗
    • 液體培養
    • 固體培養法
  • 免疫學檢測
    • ELISA
    • 西方墨點法
  • 分子檢測
    • 線探針檢測
    • PCR
  • 快速診斷測試
    • 層析法
    • 側向流

第8章 結核病檢測市場：依技術分類

  • 培養方法
  • 免疫診斷方法
  • 脂阿拉伯甘露聚醣測定
  • 核酸增幅檢查

第9章 結核病檢測市場：依樣本類型分類

  • 血
  • 痰
  • 尿

第10章 結核病檢測市場：依最終用戶分類

  • 診所
  • 醫院
  • 測試機構

第11章 結核病檢測市場：依通路分類

  • 診斷檢測實驗室
  • 醫院藥房
  • 網路藥房

第12章 結核病檢測市場：依應用領域分類

  • 活動性肺結核
  • 潛伏性結核病

第13章 結核病檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 結核病檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 結核病檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMerieux SA
  • Bruker Corporation.
  • Creative Diagnostics
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hologic, Inc.
  • Kindstar Globalgene Technology, Inc.
  • Lionex GmbH
  • Molbio Diagnostics Limited
  • QIAGEN NV
  • Revvity, Inc.
  • SD Biosensor, Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zhejiang Di'an Diagnostics Technology Co., Ltd.
Product Code: MRR-03252A5F927A

The Tuberculosis Testing Market is projected to grow by USD 3.68 billion at a CAGR of 6.60% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.35 billion
Estimated Year [2026] USD 2.49 billion
Forecast Year [2032] USD 3.68 billion
CAGR (%) 6.60%

Tuberculosis testing is central to global TB control because timely diagnosis determines whether patients receive curative therapy, drug-resistance evaluation, and public health follow-up. According to the World Health Organization, an estimated 10.8 million people developed TB in 2023, and 1.25 million people died from the disease, underscoring the need for faster, more accessible diagnostic pathways.

The tuberculosis testing landscape spans tuberculin skin tests, interferon-gamma release assays, smear microscopy, culture, nucleic acid amplification tests, line probe assays, and urine lipoarabinomannan testing for eligible high-risk patients. Demand is being shaped by WHO recommendations favoring rapid molecular diagnostics as initial tests for symptomatic patients, rising drug-resistant TB surveillance needs, and expanded screening among vulnerable populations, including people living with HIV, household contacts, migrants, incarcerated populations, and individuals with diabetes or immunosuppression.

Transformative Shifts in the Tuberculosis Testing Landscape

The tuberculosis testing landscape is shifting from microscopy-led workflows toward rapid molecular testing, decentralized sample collection, and integrated drug-resistance detection. Culture remains essential for comprehensive susceptibility testing, but nucleic acid amplification tests can identify Mycobacterium tuberculosis and rifampicin resistance within hours, helping clinicians initiate appropriate treatment sooner and supporting public health teams in interrupting transmission.

Another major shift is the expansion of active case-finding beyond traditional clinics. Mobile chest X-ray, community sputum collection, digital reporting, contact investigation, and linkage-to-care platforms are improving detection in high-burden settings. These changes support national TB programs seeking to close the gap between estimated TB incidence and the number of people who are bacteriologically confirmed and notified, while also improving access for populations that face geographic, social, or economic barriers to facility-based diagnosis.

Cumulative Impact of Artificial Intelligence on TB Testing

Artificial intelligence is increasingly influencing tuberculosis testing through computer-aided detection for chest radiography, automated laboratory quality checks, workflow prioritization, and predictive outreach. WHO has stated that computer-aided detection software may be used as an alternative to human readers for TB screening and triage in people aged 15 years and older, when implemented with appropriate calibration and confirmatory testing.

AI does not replace microbiological confirmation, but it can accelerate screening, reduce reader variability, and support targeted testing in high-volume environments. The strongest use cases combine AI triage with WHO-recommended rapid molecular tests, laboratory information systems, and governance frameworks covering bias monitoring, data security, local validation, and clinical accountability. As digital chest radiography expands in community and mobile settings, AI-enabled triage is expected to remain most valuable where it shortens the pathway from symptom screening to confirmatory molecular diagnosis and treatment initiation.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific remains the largest burden environment for tuberculosis testing, led by high-incidence countries such as India, China, Indonesia, and the Philippines. The region is prioritizing rapid molecular diagnostics, private-sector notification, community screening, and drug-resistance detection to improve case finding and shorten time to treatment. Large population bases, diverse healthcare access levels, and national TB elimination strategies make Asia-Pacific a core region for molecular tuberculosis diagnostics, digital chest X-ray screening, and laboratory network strengthening.

North America and Europe are lower-incidence regions, but testing demand persists across migrants, people experiencing homelessness, correctional settings, healthcare workers, close contacts, and immunocompromised patients. In these regions, TB testing is closely linked to latent tuberculosis infection management, infection control, high-quality laboratory confirmation, and surveillance. Latin America faces urban transmission, access gaps, and uneven diagnostic capacity, creating a need for faster testing in underserved communities and stronger linkage-to-care systems. The Middle East has heterogeneous needs linked to migrant labor, border health, and national screening programs, while Africa carries a high TB and TB/HIV burden, making rapid molecular tests, urine LAM testing for eligible people with HIV, decentralized specimen referral, and integrated TB-HIV diagnostic services especially important.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are expanding molecular tuberculosis testing, digital chest X-ray screening, and community-based case finding to address persistent transmission across high-burden and lower-burden member states. The GCC emphasizes workforce screening, migrant health protocols, centralized laboratory quality, and infection prevention in highly mobile populations. The European Union supports standardized surveillance, cross-border reporting, antimicrobial resistance monitoring, and latent TB infection management among risk groups, with testing strategies shaped by low-incidence elimination goals and migration-related health priorities.

BRICS countries represent a major share of the global TB burden and include several settings with substantial drug-resistant TB challenges, making the group critical to diagnostic adoption, local production, procurement scale, and national program implementation. G7 countries influence tuberculosis testing through innovation funding, regulatory expectations, global health financing, laboratory standards, and support for high-burden countries. NATO members focus on resilient healthcare systems, military readiness, outbreak preparedness, and infectious disease surveillance that includes TB risk management for deployed personnel, mobile populations, and vulnerable communities.

Key Country Insights Across Major Tuberculosis Testing Markets

The United States and Canada maintain low TB incidence but rely on targeted testing, contact investigations, and latent TB screening among higher-risk populations, including people born in countries with higher TB burden, individuals with HIV, and immunocompromised patients. Mexico and Brazil face larger public health needs, with molecular diagnostics supporting earlier detection in urban, remote, and underserved communities. The United Kingdom, Germany, France, Italy, and Spain emphasize migrant screening, laboratory quality, contact tracing, and latent TB prevention, while Russia remains a priority country for multidrug-resistant and rifampicin-resistant TB diagnostics due to its documented drug-resistant TB burden.

China and India are pivotal due to population scale, national TB elimination strategies, and rapid test deployment across public health networks. India continues to expand molecular testing, private-sector engagement, and active case-finding initiatives, while China combines surveillance, laboratory modernization, and targeted screening in high-risk groups. Japan, Australia, and South Korea combine low-incidence surveillance with advanced laboratory networks, rigorous contact investigation, and targeted latent TB testing. Across these countries, the strongest opportunities are linked to rapid molecular testing, culture and drug-susceptibility testing, digital notification, specimen referral systems, AI-assisted radiology screening, and programs that connect diagnosis to treatment initiation without delay.

Actionable Recommendations for Tuberculosis Testing Industry Leaders

Industry leaders should align product portfolios with WHO-recommended diagnostic algorithms, especially rapid molecular tests that detect TB and key drug-resistance markers. Commercial strategies should prioritize affordability, cartridge availability, instrument uptime, biosafety, specimen logistics, and service models that work in centralized laboratories, district hospitals, mobile screening programs, and decentralized care settings.

Organizations should also invest in interoperable digital reporting, external quality assurance, sample transport, maintenance networks, and AI-enabled screening partnerships. The most defensible strategies will combine validated diagnostics with training, supply continuity, local regulatory engagement, and evidence generation that demonstrates improved case detection, faster treatment initiation, stronger drug-resistance surveillance, and reduced loss to follow-up. Partnerships with public health programs should focus on workflow integration, not only test placement, so that screening, confirmation, reporting, and treatment linkage operate as a single patient-centered pathway.

Research Methodology

This executive summary is based on a structured review of authoritative public health and scientific sources, including WHO guidance, national TB program priorities, CDC and ECDC materials, peer-reviewed diagnostic evidence, regulatory trends, and publicly available health policy information. Insights were triangulated across disease burden, testing algorithms, procurement patterns, diagnostic technology adoption, screening guidance, and laboratory implementation signals.

The methodology emphasizes verified, data-backed interpretation rather than unsupported estimates. Regional, group, and country insights were assessed through the lens of TB incidence, drug-resistant TB burden, TB/HIV co-infection, laboratory capacity, reimbursement conditions, screening policies, and the practical role of molecular diagnostics, culture, immunological testing, urine LAM testing, and AI-assisted radiology. The analysis excludes market sizing, market share, and forecasting, focusing instead on evidence-based shifts in tuberculosis testing access, clinical utility, and public health relevance.

Conclusion

Tuberculosis testing is moving toward faster, more connected, and more patient-centered diagnostic models. The combination of rapid molecular testing, targeted screening, drug-resistance detection, AI-supported triage, and digital linkage-to-care is becoming essential for national TB programs and healthcare providers aiming to reduce transmission, improve treatment outcomes, and address persistent diagnostic gaps.

For industry participants, the opportunity is not limited to test placement. Long-term value will come from reliable access, operational support, data integration, quality assurance, and evidence-based partnerships that help close diagnostic gaps in high-burden countries while maintaining surveillance strength in low-incidence markets. Organizations that support complete diagnostic pathways-from screening and confirmatory testing to reporting and treatment initiation-will be best positioned to contribute to global TB elimination priorities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Tuberculosis Testing Market, by Test Type

  • 7.1. Culture Test
    • 7.1.1. Liquid Culture
    • 7.1.2. Solid Culture
  • 7.2. Immunological Test
    • 7.2.1. Elisa
    • 7.2.2. Western Blot
  • 7.3. Molecular Test
    • 7.3.1. Line Probe Assay
    • 7.3.2. Pcr
  • 7.4. Rapid Diagnostic Test
    • 7.4.1. Chromatographic
    • 7.4.2. Lateral Flow

8. Tuberculosis Testing Market, by Technology

  • 8.1. Culture Based Technology
  • 8.2. Immunodiagnostic
  • 8.3. Lipoarabinomannan Assay
  • 8.4. Nucleic Acid Amplification Test

9. Tuberculosis Testing Market, by Sample Type

  • 9.1. Blood
  • 9.2. Sputum
  • 9.3. Urine

10. Tuberculosis Testing Market, by End User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Reference Laboratory

11. Tuberculosis Testing Market, by Distribution Channel

  • 11.1. Diagnostic Laboratory
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy

12. Tuberculosis Testing Market, by Application

  • 12.1. Active Tuberculosis
  • 12.2. Latent Tuberculosis

13. Tuberculosis Testing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Tuberculosis Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tuberculosis Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Becton, Dickinson and Company
  • 17.3. Bio-Rad Laboratories, Inc.
  • 17.4. Biocartis Group NV
  • 17.5. bioMerieux SA
  • 17.6. Bruker Corporation.
  • 17.7. Creative Diagnostics
  • 17.8. Danaher Corporation
  • 17.9. DiaSorin S.p.A.
  • 17.10. F. Hoffmann-La Roche Ltd.
  • 17.11. Fujifilm Holdings Corporation
  • 17.12. Hologic, Inc.
  • 17.13. Kindstar Globalgene Technology, Inc.
  • 17.14. Lionex GmbH
  • 17.15. Molbio Diagnostics Limited
  • 17.16. QIAGEN N.V.
  • 17.17. Revvity, Inc.
  • 17.18. SD Biosensor, Inc.
  • 17.19. Seegene Inc.
  • 17.20. Siemens Healthineers AG
  • 17.21. Thermo Fisher Scientific Inc.
  • 17.22. Zhejiang Di'an Diagnostics Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL TUBERCULOSIS TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CULTURE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CULTURE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIQUID CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIQUID CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIQUID CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOLID CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOLID CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOLID CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WESTERN BLOT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WESTERN BLOT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WESTERN BLOT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LATERAL FLOW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LATERAL FLOW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LATERAL FLOW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. GCC TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 171. GCC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 172. GCC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 173. GCC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 174. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. G7 TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 204. G7 TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 205. G7 TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 206. G7 TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 207. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 215. NATO TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 216. NATO TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 217. NATO TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 218. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. NATO TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. NATO TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 349. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 350. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 353. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 354. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 355. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 356. JAPAN TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 357. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 358. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 359. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 360. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 361. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST,